Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | PNLIP | P16233 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770141 | 0.84 | SCN5A (0.36) | DRD2DRD4DRD3SCN5AHTR2A | |
| SCHEMBL26697694 | 0.84 | SCN5A (0.36) | DRD2DRD4DRD3SCN5AHTR2A | |
| SCHEMBL3483796 | 0.82 | PDE7A (0.41) | DRD2DRD4DRD3PDE7ASCN5A | |
| SCHEMBL29887886 | 0.77 | EGFR (0.38) | PDE7AHTR2ASLC6A4EGFRERBB2 | |
| SCHEMBL3484112 | 0.77 | EGFR (0.38) | PDE7AHTR2ASLC6A4EGFRERBB2 | |
| SCHEMBL3483989 | 0.74 | AXL (0.41) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL3484000 | 0.73 | PDE7A (0.37) | PDE7AHTR2ASLC6A4PNLIPMEN1 | |
| SCHEMBL7187883 | 0.73 | MAOB (0.55) | PDE7AHTR2ASLC6A4MEN1KMT2A | |
| SCHEMBL3064096 | 0.72 | SCN5A (0.42) | DRD2DRD4DRD3SCN5AMEN1 | |
| SCHEMBL631854 | 0.71 | PDE7A (0.49) | PDE7AHTR2ASLC6A4PNLIPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | DRD2 1841/4885DRD4 2385/4885DRD3 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.